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L-Aminocarnitine (L-AC) has been shown to inhibit carnitine palmitoyltransferases (CPT) in rat muscle and in rat liver. However, there are
no reports on interactions of L-AC with CPT II and CPT I of human muscle. Therefore, the aim of the present work was to characterize the
inhibition of human muscle CPT I and CPT II by L-AC in muscle mitochondria, skinned fibers and muscle homogenates in comparison to the
established action of malonyl-CoA. Both isoenzymes were inhibited by L-AC, but sensitivity was different (CPT I, Kd = 3.8 mM L-AC; CPT
II, Kd = 21.3 AM L-AC). A mixed inhibition type in respect to carnitine was detected (Ki = 3.5 AM L-AC). At 0.5 mM L-AC, CPT II was
completely inhibited without affection of CPT I. In contrast, CPT I was completely inhibited by 0.4 mM malonyl-CoA (Kd = 0.5 AM),
whereas CPT II was nearly not affected by this inhibitor. Using these inhibitors in muscle homogenates, activities of CPT II and CPT I were
detected to be 38F 10% and 63F 10% of total, respectively (n = 21). In intact mitochondria and different fractions of muscle homogenates
after selective solubilization of CPT II by Tween 20, the extent of specific CPT inhibition changed in relation to the accessible isoenzyme
pattern. Palmitoyl-carnitine-dependent respiration in skinned fibers was inhibited by high concentrations of L-AC, indicating that the inhibitor
can be transported via the acyl-carnitine transporter, too. The combined use of both inhibitors (L-AC and malonyl-CoA) allows the kinetic
characterization of CPT I and CPT II in human muscle homogenates. In addition, it has been shown that L-AC can be used for the study of
metabolic consequences of CPT II deficiency on function of intact mitochondria.
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1. Introduction properties of the enzyme. Detailed kinetic consequences,Carnitine palmitoyltransferases (CPT I and CPT II)
together with the acyl-carnitine translocator mediate the
transfer of acyl-groups into mitochondria. For review see
Ref. [1]. Various diseases, due to defects in enzymes of
acyl-carnitine transport, are known [2–5]. The most
frequently affected enzyme is CPT II [6], clinically almost
entirely restricted to skeletal muscle and characterized by
recurrent attacks of myoglobinuria [2,5,6]. More than 25
pathogenic mutations have been detected in the human
CPT II gene [7–11] associated with abnormal regulatory0005-2728/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbabio.2003.11.005
Abbreviations: BCA, bicinchoninic acid assay; CPT, carnitine palmi-
toyltransferase; L-AC, L-aminocarnitine; NCP, non-collagen protein
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E-mail address: frank.gellerich@medizin.uni-halle.de (F.N. Gellerich).however, on the phenotype of the enzyme are unknown.
Such investigations could be done in biopsies or cell
cultures taken for diagnostic purpose.
For kinetic investigations of CPT II in muscle homo-
genates, CPT I can be specifically inhibited by etomoxir
[12] or the physiological metabolite malonyl-CoA [1]. L-
AC is an inhibitor of CPT [13–16]. It can be converted
into acetyl-L-AC which cannot be metabolized further
[16]. There was the idea to use L-AC as antiketogenic
and hypoglycaemic drug [17]. For that purpose, in vitro
and in vivo studies in rats were performed to characterize
the effect of L-AC on CPT. It has been shown that L-AC
inhibits the activity of CPT in homogenates of rat liver
mitochondria by 64% [17]. At first, it was assumed that
L-AC inhibits both CPT isoenzymes in preparations of rat
liver mitochondria [17]. Subsequent experiments on rat
hearts suggested that L-AC should be a specific inhibitor
of CPT II [15]. This result was confirmed on rat liver
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not CPT I [14]. However, there are no reports on effects
of L-AC on CPT II and CPT I of human muscle.
The aim of the present study was to investigate the action
of L-AC on CPT I and CPT II in homogenates of human
skeletal muscle, in isolated mitochondria, and in skinned
muscle fibers. Results demonstrate the possibility to inves-
tigate kinetically CPT I as well as CPT II in muscle
homogenates of human muscle biopsies using specific
inhibitors (L-AC and malonyl-CoA) without the necessity
to separate them from each other.2. Materials and methods
Muscle specimens were obtained from patients who had
muscle biopsy for diagnostic purposes but were ultimatively
found to have no neuromuscular disease by combined
clinical, electrophysiological, histological, and biochemical
criteria. Muscle specimens were taken from m. quadriceps
(m. vastus lateralis) or m. biceps brachii by open biopsy
under local anesthesia. Samples were immediately frozen
and stored in liquid nitrogen until subsequent biochemical
studies. For investigation of mitochondrial function from
some patients, a part of muscle biopsy was stored on ice at 4
jC in high-energy preservation solution [18] after rough
dissection. It has been shown that mitochondrial function
remains intact up to 30 h under these conditions [19].
Written informed consensus was obtained from all patients
before biopsy.
2.1. Isolation and permeabilization of muscle fibers
Immediately before oxygraphic measurements, the fibers
were permeabilized for 30 min with 50 Ag saponin/ml of
preservation solution consisting of 8.1 mM K-EGTA, 1.9
mM CaEGTA buffer (free Ca2 + concentration 0.1 AM), 9.5
mM MgCl2.6H2O, 3 mM KH2PO4, 20 mM taurine, 5.2 mM
ATP, 15 mM PCr, 49 mM K+-MES, 20 mM imidazole (pH
7.1) as described previously [18]. After permeabilization,
the fibers were washed three times (10 min) in incubation
medium (see below) to remove saponin and adenine nucleo-
tides. All procedures were performed in a cooling-room on
ice at 4 jC.
2.2. Respirometric measurements
We used the OROBOROSR oxygraph [20], a two-
chamber respirometer with a Peltier thermostat and inte-
grated electromagnetic stirrers. Bundles of fibers (5–10
mg) were transferred into the oxygraph chambers. The
measurements were performed at 30jC in 1.42 ml incu-
bation medium consisting of 75 mM mannitol, 25 mM
sucrose, 100 mM KCl, 10 mM KH2PO4, 0.5 mM EDTA,
5 mM MgCl2, 20 mM Tris–HCl, and 1 mg/ml BSA (pH
7.4) [18]. The oxygen concentration in the air-saturatedmedium was considered to be 200 nmol O2/ml at 95 kPa
barometric pressure. The weight-specific oxygen con-
sumption was calculated as the time derivative of the
oxygen concentration (DATGRAPH Analysis software,
OROBOROSR).
2.3. Muscle homogenates
Frozen muscle tissue was homogenized in a glass–
glass homogenizer in nine volumes Chappel–Perry buffer
containing 50 mM Tris buffer (pH 7.5), 100 mM KCl, 5
mM MgCl2, and 1 mM EDTA [21–23]. For Tween 20
separation of both CPT, 1% Tween 20 was added to the
homogenate. After 15 min of incubation, the homogenates
were centrifuged for 30 min at 50,000 RPM using a
Beckman ultracentrifuge (L7–65) equipped with the rotor
70.1Ti. CPT activity was investigated in the supernatant
and in the pellet redissolved with the same concentration
of Tween 20.
2.4. Chemicals
All chemicals were obtained from Sigma Chemie (Dei-
senhofen/Germany). L-AC was a gift from Sigma Tau
(Rome/Italy). 14C-carnitine was obtained from NEN Life
Science Products (Ko¨ln/Germany). All other chemicals were
of reagent grade purity.
2.5. Enzyme assays
CPT was determined using a radiochemical isotope
forward assay as described previously [21–23]. In brief,
the assay system contained 10 mM Tris–HCl buffer (pH
7.6), 0.1% fatty acid-free bovine serum albumin, 1 mM
dithiothreitol, 0.08 mM palmitoyl-CoA, and 5 mM L-14C-
carnitine in a final volume of 1 ml. Temperature was 30 jC.
Experiments were performed either in the presence or in the
absence of 0.4 mM malonyl-CoA to inhibit CPT I. Con-
centration of L-AC was varied between 0 and 30 mM.
Incubations were started by the addition of homogenate
and stopped after 10 min by the addition of ammonium
sulfate and isobutene. Labelled palmitoyl-carnitine was
measured after separation of the organic phase using a
scintillation counter (Beckmann LS 6500). All measure-
ments were performed in duplicate.
2.6. Protein determination
Non-collagen protein (NCP) was determined by the
bicinchoninic acid assay (BCA) [24] (Pierce, Putbus,
The Netherlands) after digestion of the homogenate with
sodium hydroxide (50 mM) and pelleting the insoluble
collagen protein by centrifugation (12,000 g for 10
min). The BCA reagent was supplemented with 0.1%
(w/v) sodium dodecylsulfate. BSA was used as a
standard.
Fig. 2. Inhibition of CPT II by L-aminocarnitine at different
concentrations of carnitine. Kinetic investigation of CPT II in muscle
homogenates in the presence of 0.4 mM malonyl-CoA. Measurements
were performed at varied concentrations of carnitine and L-AC. Km=
0.46F 0.04 mM carnitine, Ki = 1.8F 0.3 AM L-AC. Data of three
experiments were used for calculation of kinetic constants by means
of the kinetic module from Sigma Plot assuming different inhibition
types.
K. Traufeller et al. / Biochimica et Biophysica Acta 1608 (2004) 149–154 1513. Results and discussion
3.1. Characterization of CPT inhibition by L-AC and
malonyl-CoA
Fig. 1 illustrates the inhibition of CPT I and II in
muscle homogenates by L-AC. CPT activity in the
absence and in the presence of 0.4 mM malonyl-CoA
was measured at increasing concentration of L-AC.
Normalized data of three different experiments are
shown as meansF S.E. for the total activity (circles).
The total CPT activity was inhibited by malonyl-CoA
(59%). Consisting of the prevailing view, the remain-
ing activity was assumed to be CPT II (triangles). The
activity of CPT I (squares) was calculated by subtrac-
tion of CPT II from the total activity. Increasing
additions of L-AC decreased the CPT activity within a
large range of concentration. CPT II activity was
completely inhibited at 500 AM L-AC, whereas CPT I
started to be inhibited at higher concentrations only. We
used a general curve fitting-programme which was made
for calculation of dissociation constants and further
parameters from inhibitor titration curves (see Eq. (5)Fig. 1. Inhibition of CPT by L-aminocarnitine. Activity of CPT I + II
(circles) was measured radiochemically as described in Section 2.5 using
palmitoyl-CoA and L-14C-carnitine (forward assay). Malonyl-CoA insensi-
tive CPT activity (CPT II, triangles) was assayed in the additional presence
of 0.4 mM malonyl-CoA. Malonyl-CoA sensitive CPT activity (CPT I,
squares) was calculated by subtracting CPT II from the total activity.
L-Aminocarnitine was varied between 0 and 30 mM as indicated. Data as
means of three typical experimentsF S.E. Activities were expressed as the
percentage of the activity seen without the addition of L-AC and malonyl-
CoA. Curves were fitted using a nonlinear computer model [25], allowing
the estimation of Kd and Vmax. CPT II: Kd = 21 AM L-AC, Vmax 41.1%. CPT
I: Kd = 3780 AM, L-AC, Vmax = 68.3%.in Ref. [25]). We found dissociation constants of 21.3
AM and 3.78 mM L-AC for CPT II and CPT I,
respectively. Since the inhibitor curve of total CPT
was the sum of two curves, it was not possible to
obtain a suitable curve fit for CPT I + II.
Additionally, inhibitor experiments were performed vary-
ing the concentration of L-AC and of carnitine as well (Fig.
2). With increasing inhibitor concentration, CPT II activity
was increasingly diminished, indicating that a competition
occurred between carnitine and L-AC. Using an nonlinear
regression programme kinetic constants were estimated to
be Km= 0.46F 0.04 mM carnitine and Ki = 1.8F 0.3 AM L-
AC. The best fit was obtained for a partial competitive
inhibition type.
In further experiments, the effect of malonyl-CoA on
CPT I and II was studied. In Fig. 3, both CPT activities were
plotted versus the inhibitor concentration. CPT I activity
decreased sigmoidal with increasing malonyl-CoA concen-
tration (Kd = 0.5 AM), whereas the CPT II activity was only
marginally influenced.
3.2. Detection of CPT I/CPT II ratios in human muscle
mitochondria and muscle homogenates
L-AC and malonyl-CoA were applied for individual
measurements of CPT I and CPT II in muscle homoge-
nates of 21 patients without CPT II deficiency. The relative
contents were found to be 38.1F 9.8% for CPT II and
63.4F 9.5% for CPT I. The sum of both (101.5F 7.7%)
indicates the good reproducibility of the method. The total
activity of CPT I plus CPT II was 1.7F 0.5 U/g NCP
(n = 21) in m. vastus lateralis of patients without CPT II
deficiency.
Fig. 4. Inhibition of CPT I and CPT II by malonyl-CoA and L-
aminocarnitine in soluble and particulate fractions of human skeletal
muscle obtained by Tween 20 fractionation. CPT II was released from
muscle mitochondria by incubation of muscle homogenate with 0.5%
Tween 20 and separated by centrifugation (soluble CPT II, triangles) from
particulate CPT I (pellet, circles). (A,B) Activity of CPT was measured
radiochemically without (open symbols) and with (filled symbols) 0.4 mM
malonyl-CoA as well as in the presence of L-AC as indicated. (C,D)
Activity of CPT was measured without (open symbols) and with (filled
symbols) 0.5 mM L-AC. Addition of malonyl-CoA as indicated.
Fig. 3. Inhibition of CPT by malonyl-CoA. Activity of CPT I was measured
in homogenates of human skeletal muscle in the presence (circles) of 0.5
mM L-aminocarnitine. CPT II activity (triangles) was calculated subtracting
CPT I from the total activity. Means of three typical experimentsF S.E.
Activities are expressed as the percentage of the activity measured in the
absence of inhibitors.
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bated with 1% Tween 20, which is known to selectively
release CPT II from mitochondrial inner membranes
[22,26]. After ultracentrifugation, both supernatant and
pellet fraction were incubated either with 0.5 mM L-AC,
with 0.4 mM malonyl-CoA, or without inhibitor. To these
incubations, the second inhibitor was added in increasing
concentrations as indicated. As shown in Fig. 4A, about
88% of the total CPT activity in the pellet fraction was
inhibited by malonyl-CoA (CPT I). The remaining activity
was inhibitable by L-AC, indicating that the pellet fraction
contained 12% CPT II. Corresponding results were
obtained if CPT II was at first inhibited by 500 AM L-
AC followed by an inhibitor titration with malonyl-CoA
(Fig. 4C). A completely different situation was found in
the supernatant. As shown in Fig. 4B, only a very small
part of total CPT activity was inhibited by malonyl-CoA,
but 80% of CPT was inhibited by 500 AM L-AC (Fig. 4D),
indicating that the Tween 20 supernatant indeed contained
mainly CPT II.
In isolated functionally intact human muscle mitochon-
dria, accessible CPT activity is CPT I which is localized
in the outer membrane. Therefore, as shown in Fig. 5,
measurable CPT activity was nearly completely inhibited
by 0.2 mM malonyl-CoA but was much less inhibited by
2 mM L-AC. At increasing L-AC concentration (20 mM),
CPT I also became inhibited. The lowest activity was
measured in the presence of both inhibitors. In disinte-
grated mitochondria, the matrix enzyme CPT II is acces-sible, therefore the malonyl-CoA-insensitive enzyme
activity was 37.8% similar as described above for muscle
homogenates. With increasing L-AC, the remaining activ-
ity decreased as expected.
3.3. Inhibition of palmitoyl-carnitine-dependent respiration
by L-AC
Fig. 6 shows a respirometric experiment for detection
of functional activity of CPT II in intact mitochondria of
skinned muscle fibers. Respiration of mitochondria was
stimulated by 5 mM ADP in the presence of 2 mM
malate only. Respiration under these conditions is low due
to the lacking exogenous donor for acetyl-CoA. After
addition of 60 AM palmitoyl-carnitine, state 3 respiration
Table 1
Multiple substrate inhibitor titration for investigation of functional
consequences of CPT II inhibition by L-AC
JO2 (nmol O2/mg/min) (%)
Palmitolycarnitine 0.32F 0.05 100
Malonyl-CoA (0.5 mM) 0.33F 0.11 103
L-AC (3.4 mM) 0.24F 0.04 75
L-AC (37.8 mM) 0.12F 0.02 38
Rotenone 0.08F 0.01 25
Succinate 0.45F 0.03 141
Mitochondrial respiration was measured in human skinned fibers as
described in Fig. 6. Data as mean values of eight different incu-
bationsF S.E.
Fig. 5. Different sensitivities of mitochondrial CPT in intact and frozen
human muscle mitochondria for malonyl-CoA and L-aminocarnitine. CPT
activity was measured in isolated intact human muscle mitochondria and in
a mitochondrial homogenate obtained by freezing and thawing. Remaining
activity in the presence of indicated inhibitors as percentage of activity
measured in the absence of inhibitors. Means of three experiments with
double determinationsF S.E.
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no effect on respiration, but L-AC strongly inhibited the
respiratory rate indicating either that the inhibitor was
transported into the matrix space under these conditions
or that the acyl-carnitine translocator was directly
inhibited by L-AC. That the decreased respiration is not
a result of unspecific damage of mitochondria by L-AC
can be demonstrated by addition of rotenone (inhibitor of
complex I) and the subsequent stimulation of respirationFig. 6. Respirometric investigation of CPT II activity in human muscle
mitochondria. Oxygen consumption of human muscle mitochondria in
skinned fibers of m. biceps brachii was recorded using high-resolution
respirometry as described previously [21]. Fibers (10 mg) were incubated as
described in Section 2.5. Additions: ADP, 2 mM ADP; PC, 300 AM
l-palmitoyl-carnitine; Mal.-CoA, 0.5 mM malonyl-CoA; L-AC, 2 mM
L-aminocarnitine; Rot, 20 AM rotenone; Suc, 10 mM succinate; Atrac, 10
mM atractylate. Thick line: oxygen concentration versus time of incubation,
thin line: rate of respiration.by succinate. State 4 respiration was measured after
inhibition of the AdN-translocator with atractylate.
Table 1 summarized the results from eight different
respirometric experiments. Obviously, malonyl-CoA did
not inhibit the mitochondrial function whereas, L-AC at
increasing concentrations increasingly diminished the rates
of respiration. The succinate-dependent respiration (0.45
nmol O2/mg/min) was the same as measured without both
inhibitors, indicating that L-AC has no unspecific effects on
muscle mitochondria.
In contrast to enzymatic measurements of CPT II, where
the enzyme was sensitively inhibited by L-AC, the CPT II-
dependent respiration in muscle mitochondria required
higher L-AC concentrations to be affected. The most prob-
able reason is a low affinity of L-AC to the acyl-carnitine
translocator, therefore, an elevated extramitochondrial con-
centration is required for L-AC transport into the matrix
space. Since other functional properties of mitochondria are
obviously not affected by L-AC, the respirometric protocol
shown in Fig. 6 is useful for study of consequences of CPT
II defects on the level of mitochondrial function. Chiodi et
al. [14] investigated the effect of L-AC on the palmitoyl-
carnitine-dependent respiration of rat liver mitochondria and
found an IC50 = 5 AM L-AC, which is clearly lower than
concentrations required in the experiments presented in this
work. This higher sensitivity of liver mitochondria for L-AC
inhibition could be caused by a more effective transport via
the acyl-carnitine translocator or by an increased sensitivity
of rat liver CPT II to L-AC.
Recently, it has been shown that outer membrane per-
meability for ADP is influenced by oxidation of acyl-
carnitines but not when their oxidation was prevented by
the absence of necessary cofactors or blocked with rotenone
[27]. L-AC should be an appropriate inhibitor to study this
effect which could bring more light into the bioenergetic
background of rhabdomyolysis.4. Conclusions
In conclusion, different behaviours of CPT I and CPT II
with respect to inhibitors as malonyl-CoA and L-AC allow
the investigation of individual kinetic properties of CPT I
K. Traufeller et al. / Biochimica et Biophysica Acta 1608 (2004) 149–154154and CPT II in homogenates of human skeletal muscle. Since
L-AC also inhibits CPT II within intact mitochondria, we
propose this technique as an approach to investigate kinetic
and functional consequences of decreased CPT II activity in
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